148 related articles for article (PubMed ID: 30353976)
1. Selective Optimization of Pranlukast to Farnesoid X Receptor Modulators.
Schierle S; Schmidt J; Kaiser A; Merk D
ChemMedChem; 2018 Dec; 13(23):2530-2545. PubMed ID: 30353976
[TBL] [Abstract][Full Text] [Related]
2. Structural optimization and in vitro profiling of N-phenylbenzamide-based farnesoid X receptor antagonists.
Schmidt J; Schierle S; Gellrich L; Kaiser A; Merk D
Bioorg Med Chem; 2018 Aug; 26(14):4240-4253. PubMed ID: 30026040
[TBL] [Abstract][Full Text] [Related]
3. Computer-Assisted Selective Optimization of Side-Activities-from Cinalukast to a PPARα Modulator.
Pollinger J; Schierle S; Neumann S; Ohrndorf J; Kaiser A; Merk D
ChemMedChem; 2019 Jul; 14(14):1343-1348. PubMed ID: 31141287
[TBL] [Abstract][Full Text] [Related]
4. Design and Structural Optimization of Dual FXR/PPARδ Activators.
Schierle S; Neumann S; Heitel P; Willems S; Kaiser A; Pollinger J; Merk D
J Med Chem; 2020 Aug; 63(15):8369-8379. PubMed ID: 32687365
[TBL] [Abstract][Full Text] [Related]
5. Dual Farnesoid X Receptor/Soluble Epoxide Hydrolase Modulators Derived from Zafirlukast.
Schierle S; Helmstädter M; Schmidt J; Hartmann M; Horz M; Kaiser A; Weizel L; Heitel P; Proschak A; Hernandez-Olmos V; Proschak E; Merk D
ChemMedChem; 2020 Jan; 15(1):50-67. PubMed ID: 31670489
[TBL] [Abstract][Full Text] [Related]
6. Extending the structure-activity relationship of anthranilic acid derivatives as farnesoid X receptor modulators: development of a highly potent partial farnesoid X receptor agonist.
Merk D; Lamers C; Ahmad K; Carrasco Gomez R; Schneider G; Steinhilber D; Schubert-Zsilavecz M
J Med Chem; 2014 Oct; 57(19):8035-55. PubMed ID: 25255039
[TBL] [Abstract][Full Text] [Related]
7. Structure-guided modification of isoxazole-type FXR agonists: Identification of a potent and orally bioavailable FXR modulator.
Luo G; Lin X; Li Z; Xiao M; Li X; Zhang D; Xiang H
Eur J Med Chem; 2021 Jan; 209():112910. PubMed ID: 33049605
[TBL] [Abstract][Full Text] [Related]
8. Farnesoid X receptor: from medicinal chemistry to clinical applications.
Fiorucci S; Mencarelli A; Distrutti E; Zampella A
Future Med Chem; 2012 May; 4(7):877-91. PubMed ID: 22571613
[TBL] [Abstract][Full Text] [Related]
9. Discovery of new non-steroidal farnesoid X receptor modulators through 3D shape similarity search and structure-based virtual screening.
Wang L; Si P; Sheng Y; Chen Y; Wan P; Shen X; Tang Y; Chen L; Li W
Chem Biol Drug Des; 2015 Apr; 85(4):481-7. PubMed ID: 25228339
[TBL] [Abstract][Full Text] [Related]
10. Binding mechanism of the farnesoid X receptor marine antagonist suvanine reveals a strategy to forestall drug modulation on nuclear receptors. Design, synthesis, and biological evaluation of novel ligands.
Di Leva FS; Festa C; D'Amore C; De Marino S; Renga B; D'Auria MV; Novellino E; Limongelli V; Zampella A; Fiorucci S
J Med Chem; 2013 Jun; 56(11):4701-17. PubMed ID: 23656455
[TBL] [Abstract][Full Text] [Related]
11. Medicinal chemistry of farnesoid X receptor ligands: from agonists and antagonists to modulators.
Merk D; Steinhilber D; Schubert-Zsilavecz M
Future Med Chem; 2012 May; 4(8):1015-36. PubMed ID: 22650242
[TBL] [Abstract][Full Text] [Related]
12. Fragmentation of GW4064 led to a highly potent partial farnesoid X receptor agonist with improved drug-like properties.
Flesch D; Gabler M; Lill A; Gomez RC; Steri R; Schneider G; Stark H; Schubert-Zsilavecz M; Merk D
Bioorg Med Chem; 2015 Jul; 23(13):3490-8. PubMed ID: 25934227
[TBL] [Abstract][Full Text] [Related]
13. A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase To Counter Nonalcoholic Steatohepatitis.
Schmidt J; Rotter M; Weiser T; Wittmann S; Weizel L; Kaiser A; Heering J; Goebel T; Angioni C; Wurglics M; Paulke A; Geisslinger G; Kahnt A; Steinhilber D; Proschak E; Merk D
J Med Chem; 2017 Sep; 60(18):7703-7724. PubMed ID: 28845983
[TBL] [Abstract][Full Text] [Related]
14. SAR studies on FXR modulators led to the discovery of the first combined FXR antagonistic/TGR5 agonistic compound.
Lamers C; Merk D; Gabler M; Flesch D; Kaiser A; Schubert-Zsilavecz M
Future Med Chem; 2016; 8(2):133-48. PubMed ID: 26824277
[TBL] [Abstract][Full Text] [Related]
15. Anthranilic acid derivatives as novel ligands for farnesoid X receptor (FXR).
Merk D; Gabler M; Gomez RC; Flesch D; Hanke T; Kaiser A; Lamers C; Werz O; Schneider G; Schubert-Zsilavecz M
Bioorg Med Chem; 2014 Apr; 22(8):2447-60. PubMed ID: 24685112
[TBL] [Abstract][Full Text] [Related]
16. Navigation in bile acid chemical space: discovery of novel FXR and GPBAR1 ligands.
Finamore C; Festa C; Renga B; Sepe V; Carino A; Masullo D; Biagioli M; Marchianò S; Capolupo A; Monti MC; Fiorucci S; Zampella A
Sci Rep; 2016 Jul; 6():29320. PubMed ID: 27381677
[TBL] [Abstract][Full Text] [Related]
17. Pranlukast inhibits renal epithelial cyst progression via activation of AMP-activated protein kinase.
Pathomthongtaweechai N; Soodvilai S; Chatsudthipong V; Muanprasat C
Eur J Pharmacol; 2014 Feb; 724():67-76. PubMed ID: 24360935
[TBL] [Abstract][Full Text] [Related]
18. Yangonin protects against cholestasis and hepatotoxity via activation of farnesoid X receptor in vivo and in vitro.
Gao X; Fu T; Wang C; Ning C; Liu K; Liu Z; Sun H; Ma X; Huo X; Yang X; Zou M; Meng Q
Toxicol Appl Pharmacol; 2018 Jun; 348():105-116. PubMed ID: 29660435
[TBL] [Abstract][Full Text] [Related]
19. Structure-based mechanism of cysteinyl leukotriene receptor inhibition by antiasthmatic drugs.
Luginina A; Gusach A; Marin E; Mishin A; Brouillette R; Popov P; Shiriaeva A; Besserer-Offroy É; Longpré JM; Lyapina E; Ishchenko A; Patel N; Polovinkin V; Safronova N; Bogorodskiy A; Edelweiss E; Hu H; Weierstall U; Liu W; Batyuk A; Gordeliy V; Han GW; Sarret P; Katritch V; Borshchevskiy V; Cherezov V
Sci Adv; 2019 Oct; 5(10):eaax2518. PubMed ID: 31633023
[TBL] [Abstract][Full Text] [Related]
20. Design, Synthesis, and Biological Evaluation of Novel Nonsteroidal Farnesoid X Receptor (FXR) Antagonists: Molecular Basis of FXR Antagonism.
Huang H; Si P; Wang L; Xu Y; Xu X; Zhu J; Jiang H; Li W; Chen L; Li J
ChemMedChem; 2015 Jul; 10(7):1184-99. PubMed ID: 25982493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
